Alpha:
• Mesoblast Limited (NASDAQ:MESO) announces that the FDA has confirmed the receipt of its clinical efficacy and safety data module of its rolling marketing application for cell therapy remestemcel-L for the treatment of children with steroid-refractory acute graft versus host disease, a Fast Track-tagged indication.
• The company expects to file the last module this month with a request for accelerated review. If all goes well, market launch could happen later this year.Alpha: Mesoblast advances remestemcel-L application in U.S.
Ann: MSB Files GvHD Clinical Efficacy and Safety Data with US FDA, page-46
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.49 |
Change
0.140(10.4%) |
Mkt cap ! $1.701B | |||
| Open | High | Low | Value | Volume |
| $1.37 | $1.54 | $1.37 | $23.10M | 15.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 24758 | $1.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 73626 | 3 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |